Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s282, 2023. DOI: 10.25251/skin.7.supp.282. Disponível em: https://skin.dermsquared.com/skin/article/view/2390. Acesso em: 18 apr. 2025.